Europe Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity

COVID-19
Get in-depth analysis of the COVID-19 impact on this
Market/Industry



Europe biodefense market reached $1,151.8 million in 2019 and will grow by 8.5% annually over 2020-2030 owing to the rising need for biodefense agents and equipment in the region. Highlighted with 35 tables and 41 figures, this 109-page report “Europe Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country. Based on Product, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Vaccines • Anthrax • Smallpox • Botulism • Nuclear/Radiation • E-Bola • Zika • Other Vaccines Biothreat Detection Devices • Detectors/Triggering Devices • Assays and Reagents • Samplers • Identifiers Antibiotics Masks Other Products Based on Sales Channel, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Online Sales • Offline Sales Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Military • Civilian Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Achaogen, Inc. Alexeter Technologies LLC Alnylam Pharmaceuticals, Inc. Altimmune, Inc. Bavarian Nordic AS BioFactura, Inc. Cleveland Biolabs, Inc. Dynavax Technologies Inc Dynport Vaccine Company LLC (DVC) Elusys Therapeutics, Inc. Emergent BioSolutions Inc General Dynamics Corp. GlaxoSmithKline Plc Ichor Medical Systems Mediimmune (AstraZeneca) Nanotherapeutics, Inc. Ology Bioscience PathSensors Inc Pluristem Therapeutics Sanofi Pasteur Ltd. SIGA Technologies, Inc. Soligenix, Inc. Xoma Corporation (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)


1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 7
1.2 Research Methodology 10
1.2.1 Overview of Market Research Methodology 10
1.2.2 Market Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 18
2.1 Market Size and Forecast 18
2.2 Major Growth Drivers 19
2.3 Market Restraints and Challenges 22
2.4 Emerging Opportunities and Market Trends 25
2.5 Porter’s Fiver Forces Analysis 29
3 Segmentation of Europe Market by Product 33
3.1 Market Overview by Product 33
3.2 Vaccines 35
3.2.1 Anthrax 38
3.2.2 Smallpox 39
3.2.3 Botulism 40
3.2.4 Nuclear/Radiation 41
3.2.5 E-Bola 42
3.2.6 Zika 43
3.2.7 Other Vaccines 44
3.3 Biothreat Detection Devices 45
3.4 Antibiotics 47
3.5 Masks 48
3.6 Other Products 49
4 Segmentation of Europe Market by Sales Channel 50
4.1 Market Overview by Sales Channel 50
4.2 Online Sales 52
4.3 Offline Sales 53
5 Segmentation of Europe Market by Application 54
5.1 Market Overview by Application 54
5.2 Military 56
5.3 Civilian 57
6 European Market 2019-2030 by Country 58
6.1 Overview of European Market 58
6.2 Germany 61
6.3 UK 63
6.4 France 65
6.5 Spain 67
6.6 Italy 69
6.7 Russia 71
6.8 Rest of European Market 73
7 Competitive Landscape 75
7.1 Overview of Key Vendors 75
7.2 New Product Launch, Partnership, Investment, and M&A 78
7.3 Company Profiles 79
Achaogen, Inc. 79
Alexeter Technologies LLC 81
Alnylam Pharmaceuticals, Inc. 82
Altimmune, Inc. 83
Bavarian Nordic AS 84
BioFactura, Inc. 85
Cleveland Biolabs, Inc. 86
Dynavax Technologies Inc 87
Dynport Vaccine Company LLC (DVC) 88
Elusys Therapeutics, Inc. 89
Emergent BioSolutions Inc 90
General Dynamics Corp. 91
GlaxoSmithKline Plc 92
Ichor Medical Systems 93
Mediimmune (AstraZeneca) 94
Nanotherapeutics, Inc. 95
Ology Bioscience 96
PathSensors Inc 97
Pluristem Therapeutics 98
Sanofi Pasteur Ltd. 99
SIGA Technologies, Inc. 100
Soligenix, Inc. 101
Xoma Corporation 102
8 Investing in Europe Market: Risk Assessment and Management 103
8.1 Risk Evaluation of Europe Market 103
8.2 Critical Success Factors (CSFs) 106
Related Reports and Products 109


Table 1.  Snapshot of Europe Biodefense Market, 2019-2030 17
Table 2.  Main Product Trends and Market Opportunities in Europe Biodefense Market 25
Table 3. Europe Biodefense Market by Product, 2019-2030, $ mn 33
Table 4. Europe Biodefense Market: Vaccines by Application, 2019-2030, $ mn 36
Table 5. List of Biodefense Vaccine Pipelines 37
Table 6. Europe Biodefense Market: Vaccines Biothreat Detection Devices by Type, 2019-2030, $ mn 46
Table 7. Europe Biodefense Market by Sales Channel, 2019-2030, $ mn 50
Table 8. Europe Market by Application, 2019-2030, $ mn 54
Table 9. Europe Biodefense Market by Country, 2019-2030, $ mn 60
Table 10. Germany Biodefense Market by Product, 2019-2030, $ mn 62
Table 11. Germany Biodefense Market by Sales Channel, 2019-2030, $ mn 62
Table 12. Germany Biodefense Market by Application, 2019-2030, $ mn 62
Table 13. UK Biodefense Market by Product, 2019-2030, $ mn 64
Table 14. UK Biodefense Market by Sales Channel, 2019-2030, $ mn 64
Table 15. UK Biodefense Market by Application, 2019-2030, $ mn 64
Table 16. France Biodefense Market by Product, 2019-2030, $ mn 66
Table 17. France Biodefense Market by Sales Channel, 2019-2030, $ mn 66
Table 18. France Biodefense Market by Application, 2019-2030, $ mn 66
Table 19. Spain Biodefense Market by Product, 2019-2030, $ mn 68
Table 20. Spain Biodefense Market by Sales Channel, 2019-2030, $ mn 68
Table 21. Spain Biodefense Market by Application, 2019-2030, $ mn 68
Table 22. Italy Biodefense Market by Product, 2019-2030, $ mn 70
Table 23. Italy Biodefense Market by Sales Channel, 2019-2030, $ mn 70
Table 24. Italy Biodefense Market by Application, 2019-2030, $ mn 70
Table 25. Russia Biodefense Market by Product, 2019-2030, $ mn 72
Table 26. Russia Biodefense Market by Sales Channel, 2019-2030, $ mn 72
Table 27. Russia Biodefense Market by Application, 2019-2030, $ mn 72
Table 28. Biodefense Market in Rest of Europe by Country, 2019-2030, $ mn 74
Table 29. Achaogen, Inc.: Company Snapshot 79
Table 30. Achaogen, Inc.: Business Segmentation 79
Table 31. Achaogen, Inc.: Product Portfolio 80
Table 32. Achaogen, Inc.: Revenue, 2016-2018, $ mn 80
Table 33. Achaogen, Inc.: Recent Developments 80
Table 34.  Risk Evaluation for Investing in Europe Market, 2019-2030 104
Table 35. Critical Success Factors and Key Takeaways 107


Figure 1. Research Method Flow Chart 10
Figure 2. Breakdown of Primary Research 12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 5. Europe Biodefense Market, 2019-2030, $ mn 18
Figure 6. Primary Drivers and Impact Factors of Europe Biodefense Market 19
Figure 7. Primary Restraints and Impact Factors of Europe Biodefense Market 22
Figure 8. Investment Opportunity Analysis 26
Figure 9. Porter’s Fiver Forces Analysis of Europe Biodefense Market 29
Figure 10. Breakdown of Europe Biodefense Market by Product, 2019-2030, % of Sales Revenue 33
Figure 11. Europe Addressable Market Cap in 2020-2030 by Product, Value ($ mn) and Share (%) 34
Figure 12. Europe Biodefense Market: Vaccines, 2019-2030, $ mn 35
Figure 13. Europe Biodefense Market: Anthrax, 2019-2030, $ mn 38
Figure 14. Europe Biodefense Market: Smallpox, 2019-2030, $ mn 39
Figure 15. Europe Biodefense Market: Botulism, 2019-2030, $ mn 40
Figure 16. Europe Biodefense Market: Nuclear/Radiation, 2019-2030, $ mn 41
Figure 17. Europe Biodefense Market: E-Bola, 2019-2030, $ mn 42
Figure 18. Europe Biodefense Market: Zika, 2019-2030, $ mn 43
Figure 19. Europe Biodefense Market: Other Vaccines, 2019-2030, $ mn 44
Figure 20. Europe Biodefense Market: Biothreat Detection Devices, 2019-2030, $ mn 45
Figure 21. Europe Biodefense Market: Antibiotics, 2019-2030, $ mn 47
Figure 22. Europe Biodefense Market: Masks, 2019-2030, $ mn 48
Figure 23. Europe Biodefense Market: Other Products, 2019-2030, $ mn 49
Figure 24. Breakdown of Europe Biodefense Market by Sales Channel, 2019-2030, % of Sales Revenue 50
Figure 25. Europe Addressable Market Cap in 2020-2030 by Sales Channel, Value ($ mn) and Share (%) 51
Figure 26. Europe Biodefense Market: Online Sales, 2019-2030, $ mn 52
Figure 27. Europe Biodefense Market: Offline Sales, 2019-2030, $ mn 53
Figure 28. Breakdown of Europe Market by Application, 2019-2030, % of Revenue 54
Figure 29. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 55
Figure 30. Europe Biodefense Market: Military, 2019-2030, $ mn 56
Figure 31. Europe Biodefense Market: Civilian, 2019-2030, $ mn 57
Figure 32. Breakdown of European Biodefense Market by Country, 2019 and 2030, % of Revenue 59
Figure 33. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 60
Figure 34.  Biodefense Market in Germany, 2019-2030, $ mn 61
Figure 35.  Biodefense Market in UK, 2019-2030, $ mn 63
Figure 36.  Biodefense Market in France, 2019-2030, $ mn 65
Figure 37.  Biodefense Market in Spain, 2019-2030, $ mn 67
Figure 38.  Biodefense Market in Italy, 2019-2030, $ mn 69
Figure 39.  Biodefense Market in Russia, 2019-2030, $ mn 71
Figure 40.  Biodefense Market in Rest of Europe, 2019-2030, $ mn 73
Figure 41. Growth Stage of Europe Biodefense Industry over the Forecast Period 75

Let our analyst help you with a customized solution for your market research needs

Select the license

Credit card Logo
hkjkhjkhjkhjkmjhjhkhjkjkhjkhjkm
Discount  Check Discount Question  Enquiry Before
   Purchase
hkjkhjkhjkhjkmjhjhkhjkjkhjkhjkm
fgfhfhfgf